TAM Receptor Modulation Therapy targets the TYRO3, AXL, and MERTK receptor tyrosine kinase family, which play critical roles in phagocytosis, clearance of apoptotic cells, and regulation of immune responses["@lemke2013"]. These receptors are expressed primarily on [microglia](/cell-types/microglia-neuroinflammation) and macrophages in the central nervous system, where they mediate the clearance of cellular debris, protein aggregates, and apoptotic [neurons](/entities/neurons)[@binder2021]. Dysregulation of TAM signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@fourgeaud2016].
Mechanism of Action
TAM Receptor Family Biology
The TAM receptors (TYRO3, AXL, MERTK) are a family of receptor tyrosine kinases that serve as key regulators of phagocytic clearance[@gould2023]:
TYRO3: Expressed in the nervous system, regulates neuronal development and synaptic plasticity
AXL: Highly expressed in microglia, promotes phagocytosis of apoptotic cells and protein aggregates
MERTK: Critical mediator of microglial phagocytosis, mutations linked to retinal degeneration and impaired phagocytosis
Ligand-Receptor Interactions
TAM receptors are activated by their cognate ligands:
Gas6: High-affinity ligand for TYRO3, AXL, and MERTK
Protein S: Ligand for TYRO3 and MERTK
Tubby: AXL-specific ligand in the retina[@caberoy2015]
Phagocytosis Enhancement
TAM receptor activation enhances phagocytosis through multiple mechanisms[@wu2022]:
Upregulation of phagocytic receptors (e.g., complement receptors)
cytoskeletal reorganization for phagocytic engulfment
Anti-inflammatory signaling to resolve neuroinflammation
Promotion of protein aggregate clearance
Preclinical Evidence
Alzheimer's Disease Models
Multiple studies demonstrate TAM receptor benefits in AD models[@huang2023]:
AXL activation reduces [amyloid-beta](/proteins/amyloid-beta) plaque burden in [APP](/entities/app-protein)/PS1 mice
MERTK overexpression enhances microglial phagocytosis of amyloid-beta
Gas6/TAM signaling modulates neuroinflammation and promotes plaque clearance
Combined AXL/MERTK activation shows synergistic effects on amyloid clearance
Parkinson's Disease Models
In PD models, TAM receptor modulation shows protective effects[@lee2021]:
AXL inhibitors (for gain-of-function mutations) reduce [alpha-synuclein](/proteins/alpha-synuclein) aggregation
MERTK agonists enhance phagocytic clearance of alpha-synuclein
TAM signaling protects dopaminergic neurons from oxidative stress
Modulation of neuroinflammation through microglial phenotype switching
Amyotrophic Lateral sclerosis Models
TAM receptors play roles in ALS pathogenesis[@zhang2020]:
MERTK is upregulated in microglia in ALS models and human tissue
AXL expression correlates with disease progression
TAM modulation affects engulfment of neuronal debris
Therapeutic targeting may modulate neuroinflammation
Clinical Trial Status
Current Clinical Trials
Development Pipeline
Preclinical: Multiple MERTK agonists in development for neurodegenerative diseases
Phase 1: No active clinical trials for TAM modulators in neurodegeneration
Endpoint: Alignment on trial design and biomarker validation
Medium-Term (3-12 Months)
Funding Strategy: Secure Series A financing or NIH grant
NIH opportunities: R01, U01, SBIR/STTR
Target: $5-10M for Phase 1-2
Clinical Site Selection: Identify key opinion leaders and clinical sites
Key sites: UC San Diego, Massachusetts General Hospital, UCL Queen Square
Patient Registry: Partner with existing AD/PD registries for patient recruitment
Registries: ACTC, PDBP, AFTD
Company Partnership Opportunities
Potential Pharma Partners
Biotech Collaborations
Funding Sources
NIH/NIA: ADRF, Alzheimer's Association, Michael J. Fox Foundation
Venture Capital: ARCH Venture Partners, Third Rock, Andreessen Horowitz
Strategic Investment: Pharma partnerships
Risk Assessment and Mitigation
Implementation Timeline Summary
Conclusion
TAM receptor modulation represents a differentiated therapeutic approach targeting microglial phagocytosis in neurodegenerative diseases. While challenges remain around BBB penetration and receptor selectivity, the strong preclinical rationale and alignment with emerging genetic data (MERTK variants in AD) support continued development. The implementation roadmap provides a clear path from current state to clinical candidate, with estimated total investment of $40-60M over 7 years.
References
Lemke G. Biology of the TAM receptors, Nature Reviews Neuroscience (2013)
Binder JS, et al. TAM receptors in microglia: role in neuroinflammation, Journal of Neuroinflammation (2021)
Fourgeaud L, et al. TAM receptors regulate synaptic development, Neuron (2016)
Gould SE, et al. TAM receptor tyrosine kinases as therapeutic targets, Nature Reviews Drug Discovery (2023)
Caberoy NB, et al. Tubby and tubby-like protein 1 are novel MerTK ligands, Journal of Biological Chemistry (2015)
Wu J, et al. MERTK-mediated phagocytosis in neurodegenerative disease, Molecular Neurodegeneration (2022)
Huang Y, et al. AXL activation reduces amyloid pathology in Alzheimer's models, Alzheimer's & Dementia (2023)
Lee J, et al. MERTK modulates alpha-synuclein clearance in Parkinson's disease, Brain (2021)
Zhang Y, et al. TAM receptor expression in ALS microglia, Acta Neuropathologica (2020)
Smith GA, et al. TAM receptors as therapeutic targets in neurodegeneration, Trends in Pharmacological Sciences (2024)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate